GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Glaukos Corp (GKOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite positive analyst ratings and strong financial growth trends, the stock's recent price performance, technical indicators, and lack of immediate trading signals suggest waiting for a better entry point.
The stock's MACD is negatively expanding, RSI is neutral but leaning towards oversold territory, and the price is below key pivot levels. The SMA trend is bullish, but the stock is currently trading near its support levels, indicating potential short-term weakness.
Analysts have consistently raised price targets, with a consensus of strong growth potential driven by iDose and Epioxa products.
Hedge funds are significantly increasing their positions in the stock.
Financial performance shows robust revenue growth and improving gross margins.
Recent price action shows a -2.83% drop in regular market trading and a -0.33% pre-market decline.
No recent news or significant event-driven catalysts.
The stock has a higher probability of short-term declines based on candlestick pattern analysis.
In Q4 2025, revenue increased by 35.66% YoY, net income improved significantly (up 298.03% YoY), and gross margin rose to 77.8%. However, the company remains unprofitable with a negative EPS of -2.32.
Analysts are overwhelmingly positive on the stock, with multiple firms raising price targets (ranging from $127 to $160) and maintaining Buy or Overweight ratings. They highlight strong growth prospects for iDose and Epioxa products, as well as a favorable long-term outlook for the company.
